Logo image
Back
Portal Vein Thrombosis and Splenic Infarction in a COVID-19 Patient
Journal article   Open access   Peer reviewed

Portal Vein Thrombosis and Splenic Infarction in a COVID-19 Patient

Abdul Rehman, Anoop Jose Thoppil and Sara L. Wallach
Curēus (Palo Alto, CA), v 13(8), 16843
02 Aug 2021
DOI: https://doi.org/10.7759/cureus.16843
PMID: 34513429
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.7759/cureus.16843View
Published, Version of Record (VoR) Open

Abstract

General & Internal Medicine Life Sciences & Biomedicine Medicine, General & Internal Science & Technology
COVID-19 is a novel viral infection that primarily affects the lungs and runs the gamut from a mild, self-limiting, febrile illness to respiratory failure and death. It manifested as a global pandemic in 2020 and has since claimed millions of lives. Only a few months into this pandemic, it became evident that the viral infection leads to a hypercoagulable state. Anticoagulants became a standard and important part of therapy while d-dimer became a useful test to guide the choice of the anticoagulant (therapeutic vs prophylactic Lovenox). What remains unclear is how viral pneumonia can cause hypercoagulability, especially when it leads to thrombosis in unusual sites such as the portal vein. Another important question that remains unanswered is the duration of anticoagulation after discharge in the outpatient setting. Our case report addresses both these questions with an intriguing patient who presented with abdominal pain as the chief complaint in the absence of any respiratory symptoms whatsoever.

Metrics

5 Record Views
5 citations in Web of Science

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Medicine, General & Internal
Logo image